农业指数ETF-VanEck Vectors MOO 深 沪
已收盘 08-15 16:00:00 美东时间
73.77
+0.410
+0.56%
华盛通- 最 高73.91
- 今 开73.25
- 成交量 5.26万股
- 最 低 73.25
- 昨 收 73.36
- 总市值 6.23亿
- 52周最高 75.74
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 59.58
- 委 比 42.86%
- 总股本 845.00万
- 历史最高 102.907
- 量 比 1.54
- 振 幅 0.90%
- 历史最低 28.8085
- 每 手 1
- 风险率 2.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moomoo Ensures Shares for 100% of Its Subscribers in Bullish IPO Allocation; Enhances Investor Experience with AI-Powered Tools
Moomoo, a global investment and trading platform, successfully secured IPO shares for all its subscribers in the Bullish IPO. The platform offers comprehensive research tools, including Moomoo AI, an advanced chatbot providing expert-level analysis on stocks, ETFs, and IPOs. Additionally, Moomoo fosters a community-driven environment for investors to exchange insights and refine strategies. CEO Neil McDonald emphasized Moomoo's commitment to demo...
08-14 12:00
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
<p>GRI Bio, Inc. announced that its CEO, Marc Hertz, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. The video webcast is available on virtualinvestorco.com and the Company's website. GRI Bio focuses on NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, with its lead program, GRI-0621, targeting idiopathic pulmonary fibrosis.</p>
07-22 12:45
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. has completed patient enrollment for its Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF). The interim safety results from 2 and 6 weeks showed GRI-0621 to be safe and well-tolerated in 12 and 24 patients, respectively. No hyperlipidemia was observed, and biomarker changes suggest an anti-fibrotic effect. The company expects to report 6-week interim biomarker data in July 2025 and topline results in Q3 202...
07-01 12:45
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio公司报告其GRI-0621在治疗特发性肺纤维化的IIa期研究中，中期安全数据显示药物安全且耐受性良好，未见显著副作用。当前IPF治疗选择有限，且效果有限。GRI-0621有望成为更有效的治疗方案。进一步数据预计将于2025年第三季度发布。
06-26 12:00
上交会UNIDO主题日 | 冰轮环境与您共探全球工业可持续发展新路径
（转自：冰轮环境） 近日，第十一届中国（上海）国际技术进出口交易会联合国工业发展组织（UNIDO）主题日活动成功举办。以“深化国际合作，促进产业可持续开放式创新...
06-23 11:15
Complexity stops investors opening SMSFs: moomoo launches one-stop service for them
Moomoo Australia and New Zealand's survey reveals that complexity, cost, and investment uncertainty are key barriers for Australians interested in opening self-managed super funds (SMSFs). To address these concerns, Moomoo simplifies SMSF setup, offers transparent fees, and provides expert resources and AI tools to streamline investing. The survey also highlights strong interest in AI for investment strategy, analysis, and compliance, with 67% of...
06-19 04:16
Mosaic Lowers 2025 Phosphate Output Guidance, Stock Dips On Revised Outlook
Mosaic Company shares slipped Friday after the company revised its second-quarter and full-year 2025 outlook.
06-06 20:48
Tyson Foods' Says Reintroducing Antibiotics Yields Healthier Chickens
Tyson Foods Inc. (NYSE: TSN) reports improved poultry health after reintroducing certain antibiotics, resulting in better weight gain and reduced mortality rates. CEO Donnie D. King notes this shift, part of a broader efficiency strategy, has strengthened their chicken business. Tyson remains committed to avoiding antibiotics critical to human medicine, reflecting its balanced approach amid rising costs and surplus supply.
2024-05-16 23:21
Why Animal Health-Focused Zoetis Shares Are Trading Higher Today
Zoetis Inc (NYSE: ZTS) beats revenue expectations with 10% Y/Y increase. U.S. segment up 16%, international up 3%. FY24 guidance revised higher. ZTS shares up 4.66%.
2024-05-02 22:08
Rising Stars, Falling Trends: July's Industry ETF Winners and Losers
As July comes to an end, it’s time to take a look at the best- and worst-perfor...
2023-07-31 22:59
